Anthurium: The innovative drug APH03571 tablets of the wholly-owned subsidiary have obtained the acceptance of the clinical trial registration application.

Announcement from Yipinhong: The drug clinical trial application for the innovative drug APH03571 developed by its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration, and they have received the "Acceptance Notice".